% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Thierauf:277316,
      author       = {J. C. Thierauf$^*$ and S. T. Kaluziak and E. Codd and S. N.
                      Dybel and S. Jobbagy and R. Purohit and A. A. Farahani and
                      A. Dedeilia and V. Naranbhai and M. P. Hoang and A. S. Fisch
                      and L. Ritterhouse and G. M. Boland and J. K. Lennerz and A.
                      J. Iafrate},
      title        = {{P}rognostic biomarkers for survival in mucosal melanoma.},
      journal      = {Pigment cell $\&$ melanoma research},
      volume       = {36},
      number       = {5},
      issn         = {1755-1471},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2023-01334},
      pages        = {378-387},
      year         = {2023},
      note         = {#EA:A102# / 2023 Sep;36(5):378-387},
      abstract     = {Mucosal melanoma (MM) is a rare subtype of melanoma with an
                      aggressive clinical course. In cutaneous melanoma (CM), the
                      absence of pigmentation and presence of NRAS/KRAS mutations
                      are biomarkers indicating an aggressive clinical course with
                      shorter overall survival. Similar data for MM are missing.
                      We present the real-world outcome data in a cohort of
                      genotyped MM patients and assessed the prognostic relevance
                      of pigmentation- and NRAS/KRAS mutation status. We
                      correlated pathological reports and clinical data with
                      overall survival of patients with MM. Furthermore, we
                      performed clinically integrated molecular genotyping and
                      analyzed real world treatment regimens for covariates
                      associated with clinical outcome. We identified 39 patients
                      with available clinical and molecular data. Patients with
                      amelanotic MM had a significantly shorter overall survival
                      (p = .003). In addition, the presence of a NRAS or KRAS
                      mutation was significantly associated with poor overall
                      survival (NRAS or KRAS p = .024). Currently, it is unknown
                      if the same prognostic relevance for the lack of
                      pigmentation and RAS mutations in CM, exists in MM. Here we
                      analyzed a cohort of MM for outcome measures and determined
                      that two known prognostic biomarkers for CM are in fact
                      novel prognosticators for MM.},
      keywords     = {genotyping (Other) / mucosal melanoma (Other) /
                      pigmentation (Other) / prognostic biomarkers (Other)},
      cin          = {A102},
      ddc          = {610},
      cid          = {I:(DE-He78)A102-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37390098},
      doi          = {10.1111/pcmr.13104},
      url          = {https://inrepo02.dkfz.de/record/277316},
}